By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1510-8 Bongcheon-dong, Kwanak-gu

Seoul    151-818  Korea
Phone: 82-2-2102-7214 Fax: 82-2-2102-7280



Company News
ViroMed Approved To Start Trial Of Gene Therapy For Ischemic Heart Disease 8/3/2016 12:05:04 PM
ViroMed Of Korea Receives U.S. Fast Track Status For Gene Therapy 5/20/2016 9:44:47 AM
ViroMed Publishes Results From Critical Limb Ischemia (CLI) Phase II Clinical Study 1/22/2016 10:07:27 AM
bluebird bio (BLUE), ViroMed Forge $49 Million+ Pact to Develop CAR T-Cell Therapies 12/3/2015 10:19:00 AM
FDA Approves Initiation Of ViroMed's VM202 For Phase III Clinical Study Of Chronic Non-Healing Ischemic Diabetic Foot Ulcer 9/1/2015 10:33:40 AM
ViroMed Takes One Step Closer to Finding a Cure for Diabetic Neuropathy through US Clinical Trial I/II 10/14/2011 11:02:32 AM
ViroMed Receives Approval for VM202 Phase II Trial in China 10/11/2011 12:41:47 PM
ViroMed and Enlyten Medical Technologies Sign Licensing Agreement to Develop Humanized Antibody to TAG-72 for Cancer Detection 2/25/2011 9:49:04 AM
Formatech, Inc.'s "Fillanthropy Program" Donates Services to Formulate and Fill ViroMed's VM206 Vaccine Targeting Breast Cancer 1/5/2010 9:40:51 AM
ViroMed Receives US FDA Approval of Phase II Trial for VM202 to Treat Peripheral Artery Disease 7/21/2009 1:59:18 PM